Exclusive Summary

• World's first lyophilized mRNA Herpes Zoster (Shingles) vaccine to enter clinical trials, overcoming the ultra-cold chain logistics barrier inherent to traditional mRNA vaccines.
• Currently in Phase I Clinical Trial (CDE approved), built on a proprietary full-domain mRNA technology platform with comprehensive IP coverage, minimizing patent infringement risks.
• Positioned as a potential "Best-in-Class" product, targeting the global aging market with superior stability and accessibility compared to GSK's Shingrix and other frozen liquid mRNA competitors.

Asset Materials

Contact Us for Full Materials